AG-73305 is a first-in-class Fc-fusion protein designed by Allgenesis. It is being developed as a treatment for DME and wAMD to prevent vision loss. AG-73305 was designed to simultaneously bind several targets that are believed to be involved in the development of DME and wAMD, in order to provide better efficacy compared to monotherapy, and reduce treatment burden.
Diabetic Macular Edema / wet Age-related Macular Degeneration / Diabetic Retinopathy / Angioid Streaks / Non-Proliferative Diabetic Retinopathy
Mechanism of Action
AG-73305 inhibits both VEGF and integrin pathways to block neovascularization, fibrosis, and inflammation observed in the affected eyes of DME patients.